Articles
Effect of monthly high-dose vitamin D supplementation on
falls and non-vertebral fractures: secondary and post-hoc
outcomes from the randomised, double-blind,
placebo-controlled ViDA trial
Kay-Tee Khaw, Alistair W Stewart, Debbie Waayer, Carlene M M Lawes, Les Toop, Carlos A Camargo Jr, Robert Scragg
Summary
Background Adults with low concentrations of 25-hydroxyvitamin D (25[OH]D) in blood have an increased risk of falls Lancet Diabetes Endocrinol 2017
and fractures, but randomised trials of vitamin D supplementation have had inconsistent results. We aimed to assess Published Online
the effect of high-dose vitamin D supplementation on fractures and falls. April 28, 2017
http://dx.doi.org/10.1016/
S2213-8587(17)30103-1
Methods The Vitamin D Assessment (ViDA) Study was a randomised, double-blind, placebo-controlled trial of healthy
See Online/Comment
volunteers aged 50–84 years conducted at one centre in Auckland, New Zealand. Participants were randomly assigned
http://dx.doi.org/10.1016/
to receive either an initial oral dose of 200 000 IU (5·0 mg) colecalciferol (vitamin D 3) followed by monthly 100 000 IU S2213-8587(17)30140-7
(2·5 mg) colecalciferol or equivalent placebo dosing. The prespecified primary outcome was cardiovascular disease Department of Public Health
and secondary outcomes were respiratory illness and fractures. Here, we report secondary outcome data for fractures and Primary Care, University of
and post-hoc outcome data for falls. Cox proportional hazards models were used to estimate hazard ratios (HRs) for Cambridge, Cambridge, UK
(Prof K-T Khaw MBBChir); School
time to first fracture or time to first fall in individuals allocated vitamin D compared with placebo. The analysis of
of Population Health,
fractures included all participants who gave consent and was by intention-to-treat; the analysis of falls included all University of Auckland,
individuals who returned one or more questionnaires. This trial is registered with the Australian New Zealand Auckland, New Zealand
Clinical Trials Registry, number ACTRN12611000402943. (A W Stewart BSc, D Waayer MEd,
C M M Lawes MBChB,
Prof R Scragg MBBS);
Findings Between April 5, 2011, and Nov 6, 2012, 5110 participants were recruited and randomly assigned either Department of General
colecalciferol (n=2558) or placebo (n=2552). Two participants allocated placebo withdrew consent after randomisation; Practice, University of Otago,
thus, a total of 5108 individuals were included in the analysis of fractures. The mean age of participants was 65·9 years Christchurch, New Zealand
(Prof L Toop MBChB); and
(SD 8·3) and 2971 (58%) were men. The mean concentration of 25(OH)D in blood was 63 nmol/L (SD 24) at baseline,
Department of Emergency
with 1534 (30%) having 25(OH)D concentrations lower than 50 nmol/L. Follow-up was until July 31, 2015, with a mean Medicine, Massachusetts
treatment duration of 3·4 years (SD 0·4, range 2·5–4·2). During follow-up, 2638 participants reported having a fall, General Hospital, Harvard
1312 (52%) of 2539 in the vitamin D group compared with 1326 (53%) of 2517 in the placebo group. The HR for falls— Medical School, Boston, MA,
USA (Prof C A Camargo Jr MD)
adjusted for age, sex, ethnic origin, history of recent fall, physical activity, and baseline 25(OH)D—was 0·99 (95% CI
Correspondence to:
0·92–1·07; p=0·82) for vitamin D compared with placebo. Non-vertebral fractures were reported in 292 individuals,
Prof Kay-Tee Khaw, Clinical
156 (6%) of 2558 in the vitamin D group and 136 (5%) of 2550 in the placebo group. The adjusted HR for fractures was Gerontology Unit, University of
1·19 (95% CI 0·94–1·50; p=0·15) for vitamin D compared with placebo. 123 (2%) people died during the trial, Cambridge School of Clinical
65 assigned vitamin D and 58 allocated placebo; the difference between treatment groups was not significant. Medicine, Addenbrooke’s
Hospital, Cambridge CB3 0EQ,
UK
Interpretation High-dose bolus vitamin D supplementation of 100 000 IU colecalciferol monthly over 2·5–4·2 years kk101@medschl.cam.ac.uk
did not prevent falls or fractures in this healthy, ambulatory, adult population. Further research is needed to ascertain
the effects of daily vitamin D dosing, with or without calcium.
Funding Health Research Council of New Zealand and Accident Compensation Corporation of New Zealand.
Introduction fractures with vitamin D supplementation.5,6 Similar
Rickets and osteomalacia are well established uncertainty relates to vitamin D supplementation and
consequences of vitamin D deficiency.1 Low blood risk of falls.7–11 Incon sis tencies have been attributed
concentrations of 25-hydroxyvitamin D (25[OH]D) have variously to differences in vitamin D dosage (frequency
also been associated with increased risk of osteoporotic and amount), type of preparation (eg, colecalciferol
fractures in some observational studies.1–3 However, [vitamin D] or ergocalciferol [vitamin D]), mode
3 2
trials of vitamin D supplementation for fracture of administration (oral or intramuscular injections),
prevention have had inconsistent results. Although baseline vitamin D status of the study population, and
findings of an early trial reported a 32% reduction in use of additional calcium supplementation.
non-vertebral fractures with vitamin D and calcium The Vitamin D Assessment (ViDA) study12 was
supplementation in elderly women,4 later trials have designed to assess whether oral colecalciferol
variously reported null, increased, or decreased risk of administered as a monthly dose of 100 000 IU (2·5 mg)
www.thelancet.com/diabetes-endocrinology Published online April 28, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30103-1 1
Articles
Research in context
Evidence before this study long-term clinical trials related to calcium and vitamin D intake
When the Vitamin D Assessment (ViDA) Study was planned in and health outcomes. The rationale for the ViDA trial was to do a
2010 with the primary and secondary outcomes of large randomised trial in a community-based population using a
cardiovascular disease, fractures, and acute respiratory monthly bolus dose of 100 000 IU colecalciferol (vitamin D)
3
infections, extensive observational data were available linking that was designed to raise average year-round concentrations of
low vitamin D status with increased risk of several important vitamin D in blood to 80–100 nmol/L, which are levels recorded
adverse health events. However, findings of the largest in young adults living in the tropics and associated with
randomised trial to date—the Women’s Health Initiative—had optimum health in observational studies up to 2010.
shown no effect of vitamin D and calcium supplementation on The monthly bolus dose was designed to improve compliance
cardiovascular disease, and other studies were underpowered for and public health feasibility.
cardiovascular events. For this report of secondary and post-hoc
Added value of this study
outcomes of falls and fractures, we initially searched PubMed
Results from the ViDA trial indicate that a monthly dose of
between Jan 1, 1985, and Dec 31, 2010, with the terms
100 000 IU colecalciferol, with good compliance in a healthy,
“vitamin D”, “fractures”, “falls”, and “randomized trials”, then
middle-aged, older, ambulatory population, showed no reduced
updated our search to Jan 31, 2016. Extensive reviews had been
risk of falls or fractures over 4 years.
published, including an Institute of Medicine report and
meta-analyses of randomised trials, including Cochrane reviews. Implications of all the available evidence
Meta-analyses of randomised trials of vitamin D These findings, taken in conjunction with results from other
supplementation on risk of falls and fractures—including the trials, suggest that large monthly bolus doses of vitamin D do
Cochrane reviews—had inconsistent conclusions that were not confer overall benefit either in frail elderly people or in a
attributed variously to the formulation of vitamin D (D or D), healthy, ambulatory, general population. Further study is
2 3
how vitamin D was administered (injection or orally), the needed to ascertain whether daily dosing might have
frequency of administration (daily doses or large intermittent different effects. Several international trials are ongoing to
bolus doses), additional calcium supplementation, and baseline investigate this issue (eg, VITAL in the USA [NCT01169259];
vitamin D status of the study populations. An Institute of DO-HEALTH in Europe [NCT01745263]; and FIND in Finland
Medicine report from 2011 highlighted the limited number of [NCT01463813]).
would reduce the risk of cardiovascular disease (primary Ethics approval for the study was granted by the Multi-
out come) or respiratory illness or fractures (secondary region Ethics Committee, Wellington (MEC/09/08/082)
outcomes) in a community-based population in in October, 2010. All participants gave written informed
New Zealand. We additionally obtained data for falls consent.
(post-hoc outcome). We report here the results for
fractures and falls. Randomisation and masking
We randomly allocated participants by computer to either
Methods vitamin D supplementation with colecalciferol or placebo,
Study design and participants with random block sizes of eight, ten, or 12 and stratified
We did a randomised, double-blind, placebo-controlled by ethnic origin (Māori, Pacific Islander, south Asian,
trial at the School of Population Health, University of European, or other) and 5-year age groups. Participants
Auckland Tāmaki Campus, Auckland, New Zealand.12 and study personnel were unaware of assigned groups.
We identified potential study participants from family To achieve masking, the placebo capsule was identical in
practice registers and community groups and recruited appearance to the colecalciferol preparation.
them to the study by post and subsequent follow-up
telephone calls. Inclusion criteria were: age 50–84 years, Procedures
resident in Auckland at time of recruitment, and We did baseline interviews at the School of Population
anticipated residence in New Zealand for the study Health.12 We obtained information about socio-
period. Exclusion criteria were: current use of vitamin D demographic status, lifestyle (eg, current tobacco
supplements (>600 IU per day if aged 50–70 years, smoking, alcohol consumption over the previous
>800 IU per day if aged 71–84 years); having a 12 months, and usual leisure-time physical activity over
psychiatric disorder that would limit the participant’s the previous 3 months), history of falls in the previous
ability to comply with the study protocol; a history of 4 weeks, intake of vitamin D or calcium supplements,
hypercalcaemia, nephrolithiasis, sarcoidosis, para- and medical history of osteoporosis or fracture. We also
thyroid disease, or gastric bypass surgery; or a serum- took baseline measurements of height to the nearest
corrected blood calcium concentration greater than 0·1 cm and bodyweight to the nearest 0·1 kg (in light
2·5 mmol/L. clothing without shoes), and we obtained (during the
2 www.thelancet.com/diabetes-endocrinology Published online April 28, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30103-1
Articles
morning or afternoon) a non-fasting blood sample to (A code) diagnosis or the secondary (B code) diagnosis for
screen for hypercalcaemia. We stored remaining serum specified ICD-10 codes. Second, we identified falls through
samples at –80°C for later measurement of 25(OH)D. the Accident Compensation Corporation (ACC), which is
The study drug was provided as 100 000 IU (2·5 mg) the national governmental insurance organisation that
colecalciferol capsule or identical placebo. Mailing of the covers all New Zealand residents for any medical and
capsules started in June, 2011. At the start of the hospital costs from injury. We defined fractures as claims
intervention, we sent participants two doses of the made after randomisation with specified ICD-10 or Read
capsules, to provide an initial loading dose of 200 000 IU version 2 codes (appendix p 1). We identified deaths using See Online for appendix
(5·0 mg) colecalciferol or identical placebo; thereafter, Ministry of Health mortality files.
we sent one capsule of 100 000 IU (2·5 mg) colecalciferol— We measured serum-corrected calcium the day after
equivalent to a daily dose of 3290 IU (83 μg)—or identical we had obtained blood samples at the baseline interview,
placebo, by post every month until June, 2013. From on a 183 Siemens Advia 2400 analyser (Siemens Healthcare
July, 2013, to July, 2015, we posted four capsules every Diagnostics, Eschborn, Germany) in a central laboratory.
4 months as a cost-control measure, and we emailed or We measured amounts of 25(OH)D in serum (combining
posted monthly reminders for participants to take the vitamin D and D) in baseline aliquots, which we had
2 3
capsule. We selected the monthly 100 000 IU colecalciferol stored frozen at –80°C after the baseline interview, by high-
dose because it was known to maintain amounts in performance liquid chromatography–tandem mass
serum of 25(OH)D above 90 nmol/L for at least a month spectrometry (AB Sciex API 4000; Framingham, MA,
after ingestion.13 At the time of designing the study, USA) at a laboratory participating in the Vitamin D
observational studies suggested that a range of External Quality Assessment Scheme (DEQAS). To assess For more on the DEQAS
80–100 nmol/L was associated with optimum health.14 intervention effects on concentrations in blood of 25(OH)D programme see http://www.
We gathered information about falls by self-report we randomly selected a group of participants using a list of deqas.org
using a one-page questionnaire and reply-paid envelope random numbers and asked them to return at 6, 12, 24,
in which participants were asked to report adherence, and 36 months to provide further blood samples for
falls, and fractures. The questionnaire was posted with measurement of serum-corrected calcium concentration
the study drugs every month from June, 2011, to and 25(OH)D (stored with and measured at the same time
June, 2013, then every month with the reminder letter to as the baseline blood sample for each participant).
November, 2013, then every 4 months with the study
drugs to July, 2015. Although this questionnaire has not Outcomes
been validated in this population, we used the wording The prespecified primary outcome for the ViDA trial was
recommended by expert consensus to measure falls.15 incident cardiovascular disease; prespecified secondary
We asked participants in each monthly questionnaire, outcomes were non-vertebral fractures and respiratory
“In the past month, since you took your last capsule, infection. In the registered protocol, data collection for
have you had any fall including a slip or trip in which you falls was included as a safety outcome, and the 2011
lost your balance and landed on the floor or ground or contract with a funder (the ACC) specified detailed data for
lower level?”; and in each 4-monthly questionnaire we falls. Because a formal protocol amendment was not
asked, “In the last 4 months, have you had any falls made, the falls outcome is post hoc. Results for the primary
including a slip or trip in which you lost your balance outcome (cardiovascular disease) have been reported
and landed on the floor or ground or lower level?”. If the previously,16 and findings for the other secondary outcome
participant’s response was positive, we asked them to (respiratory infection) will be reported elsewhere.
indicate the number of falls, either one or two or more We assessed self-reported adverse events using the
for the monthly questionnaire and either one, two, three, mailed questionnaire, with questions separate from
or four or more for the 4-monthly questionnaire. If a fall those for falls. We made no attempt to grade adverse
caused an injury, we asked the participant to specify events or to judge if any adverse events were related to
whether they hit their head or suffered a strain or sprain study treatment.
(to muscles or ligaments), whether they had a cut, bruise,
bleeding, or abrasion to the skin, or whether they had a Statistical analysis
fracture of a bone or bones from the fall. We classified The study sample size had 80% power (estimated post
these falls as injury falls. hoc) to detect a 10% relative reduction in falls (1% sig-
We obtained information about fractures from nificance level), assuming 50% of participants would
two sources. First, the Ministry of Health allocates all have at least one fall, based on a study in primary care
New Zealand residents a unique National Health Index showing that 24% of patients reported a fall in the
number, which we used to track hospital discharges (with previous 12 months.17 The study had an 80% chance of
International Statistical Classification of Diseases and detecting a hazard ratio (HR) of 0·76 for non-vertebral
Related Health Problems, 10th revision [ICD-10] coding) fractures (5% significance level), based on estimated
for all participants during the follow-up period. We incidence in New Zealand18 anticipating 430 people
defined fractures as hospital discharges with the primary would have fractures during the trial.
www.thelancet.com/diabetes-endocrinology Published online April 28, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30103-1 3
Articles
8851 assessed for eligibility
3601 excluded
1087 not interested
541 too high vitamin D dose
497 kidney stones
1476 other reasons
5250 baseline interview
140 excluded
92 did not return run-in questionnaire
31 high serum calcium
17 other reasons
5110 randomly assigned
2558 assigned to vitamin D 2552 assigned to placebo
3
2537 confirmed starting vitamin D during 2503 confirmed starting placebo during
3
the trial the trial
2 withdrew consent
2558 included in primary analysis of fractures 2550 included in primary analysis of fractures
(intention to treat) (intention to treat)
19 excluded from analysis of falls 33 excluded from analysis of falls
(never returned a questionnaire) (never returned a questionnaire)
2539 included in post-hoc analysis of falls 2517 included in post-hoc analysis of falls
Figure 1: Trial profile
Analysis of the falls outcome was dependent on the (in individuals allocated placebo) the HRs for falls and
number of returned questionnaires throughout the fractures associated with known risk factors. We tested
follow-up period. We included in the analysis only the proportional hazards assumptions and none was
participants who returned one or more questionnaires. violated. We treated individuals who died without having
We defined the date of the fall as approximately halfway a documented fall or fracture up to the end of follow-up
through the coverage period of the questionnaire. as censored observations.
We assumed no fall happened during the period of the Because 25(OH)D values are seasonally dependent, use
questionnaire if a questionnaire was not returned. of observed levels adds random variability to analyses;
We censored participants (ie, last date noted for estimation therefore, we calculated a deseasonalised 25(OH)D value
of follow-up time) at the last questionnaire they returned. that predicts the average level for every participant over
We analysed the fracture outcome on an intention-to- four seasons. We calculated deseasonalised concentrations
treat basis, including all participants who gave consent. using a sinusoidal model from the baseline values for all
We used the National Health Index number to identify participants.19 We defined vitamin D sufficiency in the
admissions for fracture in Ministry of Health data and protocol as having a deseasonalised value for 25(OH)D
claims for fractures in ACC data, irrespective of whether greater than 50 nmol/L (adjusted baseline >50 nmol/L for
participants continued to take part actively in the study at least 6 months of the year) for the a-priori prespecified
by returning the home questionnaire. subgroup analysis. For supplemental exploratory analyses
For the prespecified analysis of fractures, we used the for heterogeneity, we also stratified results according
Cox proportional hazards model—with robust sandwich to baseline 25(OH)D (<25 nmol/L or ≥75 nmol/L).
variance estimates and exact p values—to calculate HRs We adjusted testing of the treatment effect for stratification
based on time to first fracture for vitamin D compared variables age, sex, ethnic origin, and deseasonalised base-
with placebo. We used a similar approach for the post- line 25(OH)D. For falls, we also included history of recent
hoc analysis of falls, calculating HRs based on time to fall (in the last 4 weeks) and baseline physical activity in the
first fall. In supplemental observational analyses, to model. We assessed interactions between treatment group
assess the validity of both outcome measures we analysed and sex, age, ethnic origin, and deseasonalised 25(OH)D.
4 www.thelancet.com/diabetes-endocrinology Published online April 28, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30103-1
Articles
We also did subgroup analyses for deseasonalised Role of the funding source
baseline 25(OH)D less than 50 nmol/L and—for the fall The funders had no role in study design, data collection,
analyses—those with a history of falls and those with data analysis, data interpretation, or writing of the report.
greater physical activity, as prespecified in the protocol. RS had full access to all data in the study and takes
Although not prespecified explicitly in the protocol, responsibility for the integrity of the data and the
we did additional observational analyses of individuals accuracy of the data analysis. K-TK and RS had final
assigned placebo to examine whether risk factors for responsibility for the decision to submit for publication.
fractures and falls in this population were consistent
with those in existing observational published work and Results
to indicate that the ascertainment of these endpoints was Between April 5, 2011, and Nov 6, 2012, 47 905 people
reasonable and that this population was similar to others from 55 general practices in Auckland, New Zealand,
with respect to these risk factors. were sent an invitation letter for the ViDA study, of
This trial is registered with the Australian New Zealand whom 8851 replied and were assessed for eligibility
Clinical Trials Registry, number ACTRN12611000402943. (figure 1). 5250 individuals were eligible for the study and
agreed to a baseline interview. 140 people were excluded
Data sharing after the interview, mainly those who did not return a
Data are not available as open access because participants run-in questionnaire within 4 weeks to confirm they had
did not consent to their data being shared, apart from taken a blinded capsule. 5110 participants were randomly
with the research team. assigned either vitamin D supplementation with cole-
calciferol (n=2558) or placebo (n=2552).
Vitamin D Placebo
(n=2558) (n=2550)
Vitamin D Placebo
Men 1512 (59%) 1457 (57%)
(n=2558) (n=2550)
Women 1046 (41%) 1093 (43%)
(Continued from previous column)
Age group (years)
Past medical conditions (diagnosed by a doctor)
50–59 571 (22%) 567 (22%)
Fracture 1178 (46%) 1200 (47%)
60–69 1112 (43%) 1108 (43%)
Osteoporosis 42 (2%) 29 (1%)
70–79 716 (28%) 722 (28%)
Fall in the last 4 weeks 147 (6%) 161 (6%)
80–84 159 (6%) 153 (6%)
Confident to do daily activities without falling
Ethnic origin
Not at all 23 (1%) 25 (1%)
European or other 2127 (83%) 2126 (83%)
Quite 454 (18%) 409 (16%)
Māori 137 (5%) 135 (5%)
Completely 2076 (81%) 2113 (83%)
Pacific Islander 168 (7%) 166 (7%)
Refused to answer or unknown 5 (<1%) 3 (<1%)
South Asian 126 (5%) 123 (5%)
Anthropometry
Education (highest level)
Bodyweight (kg) 81·3 (16·5) 81·2 (16·0)
Primary school 53 (2%) 42 (2%)
BMI (kg/m²) 28·4 (5·1) 28·5 (5·1)
Secondary school 1091 (43%) 1036 (41%)
Taking supplements
Tertiary education 1412 (55%) 1470 (58%)
Vitamin D* 208 (8%) 200 (8%)
Refused to answer or unknown 2 (<1%) 2 (<1%)
Calcium 125 (5%) 127 (5%)
Employment status
Serum calcium (mmol/L) 2·3 (0·1) 2·3 (0·1)
Employed (full and part time) 1301 (51%) 1317 (52%)
Serum 25(OH)D, observed (nmol/L) 64 (24) 63 (24)
Retired 1041 (41%) 1018 (40%)
<50, observed 746 (29%) 788 (31%)
Other 211 (8%) 212 (8%)
<50, deseasonalised† 612 (24%) 658 (26%)
Refused to answer or unknown 5 (<1%) 3 (<1%)
<25‡ 46 (2%) 45 (2%)
Current tobacco smoker 164 (6%) 156 (6%)
25 to <50‡ 566 (22%) 613 (24%)
Current alcohol drinker 2177 (85%) 2211 (87%)
50 to <75‡ 1106 (43%) 1051 (41%)
Vigorous physical activity (h/week)
≥75‡ 839 (33%) 840 (33%)
0 1015 (40%) 1018 (40%)
Missing data 1 (<1%) 1 (<1%)
1–2 609 (24%) 585 (23%)
>2 804 (31%) 832 (33%) Data are number of participants (%) or mean (SD). 25(OH)D=25-hydroxyvitamin D.
*≤600 IU per day if aged 50–70 years; ≤800 IU per day if aged 71–84 years.
Refused to answer or unknown 130 (5%) 115 (5%) †Average concentration over four seasons. ‡Based on deseasonalised values.
(Table 1 continues in next column)
Table 1: Baseline characteristics
www.thelancet.com/diabetes-endocrinology Published online April 28, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30103-1 5
Articles
assigned vitamin D supplement ation and 49 (2%) allocated
Vitamin D Placebo Hazard ratio (95% CI) p value
placebo never confirmed capsule ingestion at any time
All falls (n=2638) 1312/2539 (52%) 1326/2517 (53%) 0·99 (0·92–1·07) 0·82 during the follow-up period. 122 706 questionnaires were
25(OH)D <50 nmol/L* 307/602 (51%) 316/645 (49%) 1·07 (0·91–1·25) 0·45 posted, of which 107 859 (88%) were returned. 5056 people
Fall in last 4 weeks 110/145 (76%) 109/157 (69%) 1·18 (0·89–1·56) 0·25 returned one or more questionn aires and were included
Physically active and 405/800 (51%) 412/823 (51%) 1·01 (0·88–1·16) 0·92 in the post-hoc analysis of falls (figure 1). Retention of
vigorous activity >2 h/week
participants was good during the follow-up period, with
Non-vertebral fracture (n=292) 156/2558 (6%) 136/2550 (5%) 1·19 (0·94–1·50) 0·15 2177 (86%) of 2539 individuals assigned vitamin D
25(OH)D <50 nmol/L* 34/612 (6%) 38/658 (6%) 0·94 (0·58–1·52) 0·80 supplementation and 2138 (85%) of 2517 people allocated
placebo participating actively during the last 5 months of
Data are number of participants (%) reporting a fall or having a fracture during follow-up, by study group and by
subgroups (defined on the basis of baseline measurements). Hazard ratios are relative to placebo and are adjusted for the follow-up period. 4032 (81%) partici pants returned the
sex, age, ethnic origin, history of recent fall, baseline physical activity, and baseline 25(OH)D concentration. final July, 2015, questionnaire and a further 283 (6%)
25(OH)D=25-hydroxyvitamin D. *Deseasonalised.
returned the penultimate March, 2015, questionnaire.
Table 2: Secondary and post-hoc outcomes 123 individuals died before an event up to the end of
follow-up and were censored, 65 who were assigned
vitamin D supplementation and 58 allocated placebo.
60 We do not know whether these deaths were associated
directly with a fall or fracture. Deaths did not differ
HR 0·99, 95% CI 0·92–1·07; p=0·82 between treatment groups.
Among the 5108 randomised participants, the mean
baseline concentration of 25(OH)D—not corrected for
40
season—was 63 nmol/L (SD 24), varying from a maximum
monthly mean of 77 nmol/L (22) in March to a minimum
monthly mean of 55 nmol/L (24) in August. The mean
baseline deseasonalised value (ie, amounts averaged over
20 four seasons) was 66 nmol/L (SD 23). Of 515 participants
randomly selected to return and give blood samples for
assessment of adherence, 441 accepted the invitation.
Mean baseline 25(OH)D concentrations in this sub-
0 population (unadjusted for season) were similar to those
0 1 2 3 4 in the whole cohort (61 nmol/L [SD 24]). The mean
Time in study (years)
Number at risk amount of 25(OH)D had increased substantially by
Vitamin D 2539 1724 1321 760 85
6 months among participants assigned vitamin D
Placebo 2517 1696 1278 657 91
supplementation in this subpopulation, with mean values
Figure 2: Cox proportional hazards model of falls recorded during follow-up (unadjusted for season) 54–69 nmol/L higher than in the
Lines depict the proportion of participants having a fall during follow-up, and shading represents the 95% CI.
placebo group throughout follow-up (appendix p 2). Only
HR=hazard ratio.
a few people in the vitamin D group had a 25(OH)D
Baseline characteristics of randomly assigned concentration that remained below 50 nmol/L at any
participants were similar between the vitamin D and timepoint (appendix p 2). These results are consistent
placebo groups (table 1). Mean age of participants was with the high adherence to study treatment
65·9 years (SD 8·3), with most individuals (3658 [72%] reported by participants in the returned question-
of 5110) aged 60–79 years. More men were recruited to naires (168 667 capsules [84%] were reported taken during
the study than were women (2971 [58%] vs 2139 [42%]). 200 936 person-months). Vitamin D supplement ation had
Just under half of participants (2378 [47%] of 5110) no effect on corrected serum calcium concentrations,
reported a previous fracture. Vitamin D supplements which were mean 2·3 mmol/L (SD 0·1) in each study
(within the study’s eligibility criteria) were taken by group at all timepoints, apart from at 36 months when the
408 (8%) participants. concentration was 2·4 mmol/L (0·1) in each study group.
Two participants assigned placebo withdrew their Falls were reported by just over half of all participants
consent after randomisation; therefore, 2558 people (2638 [52%] of 5056) during the follow-up period.
assigned vitamin D supplementation and 2550 allocated The probability of reporting one or more falls (the falls
placebo were included in the prespecified analysis of endpoint) was similar for those assigned to vitamin D
fractures and were followed up to July 31, 2015. Mean supplementation compared with placebo (1312 [52%]
duration of study treatment was 3·4 years (SD 0·4, of 2539 vs 1326 [53%] of 2517; HR 0·98, 95% CI 0·92–1·06,
range 2·5–4·2). 2513 (98%) of 2558 individuals assigned after adjustment for sex, age, and ethnic origin; HR 0·99,
vitamin D supplementation and 2491 (98%) of 0·92–1·07, when further adjusted for history of recent
2552 allocated placebo confirmed they had started the fall, physical activity, and baseline 25[OH]D; table 2,
study capsules within 2 months. Only 21 (1%) parti cipants figure 2). Among the participants who had a fall, the
6 www.thelancet.com/diabetes-endocrinology Published online April 28, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30103-1
)%(
llaf
a
dah
gnivah
noitroporP
Vitamin D
Placebo
Articles
proportion reporting one, two, or more than two falls did
not differ (p=0·98) between vitamin D and placebo
8
groups (respectively, 582 [44%] of 1312 vs 591 [45%] of
1326; 353 [27%] of 1312 vs 359 [27%] of 1326; and
HR 1·19, 95% CI 0·94–1·50; p=0·15
377 [29%] of 1312 vs 376 [28%] of 1326). Further more, the
number of injury falls did not differ between treatment 6
groups, with 1049 (41%) reported in 2539 participants
assigned vitamin D versus 1020 (41%) in 2517 individuals
allocated placebo (after adjustment for sex, age, ethnic 4
origin, 25[OH]D <50 nmol/L, falls in the last 4 weeks, and
vigorous activity >2 h per week: HR 1·03, 95% CI
0·95–1·13; p=0·46).
2
Subgroup analyses did not show any difference in the
risk of falls between participants allocated vitamin D
and those assigned placebo (table 2) with respect to
0
deseasonalised baseline 25(OH)D less than 50 nmol/L
0 1 2 3 4
(307 [51%] of 602 vs 316 [49%] of 645, respectively; Time in study (years)
Number at risk
p=0·45), history of falls in the 4 weeks before the baseline
Vitamin D 2558 2399 2224 1607 298
interview (110 [76%] of 145 vs 109 [69%] of 157; p=0·25), Placebo 2550 2362 2205 1487 412
or being physically active at baseline and undertaking
Figure 3: Cox proportional hazards model of fractures recorded during follow-up
vigorous activity for more than 2 h per week (405 [51%] Lines depict the proportion of participants having a fracture during follow-up, and shading represents the 95% CI.
of 800 vs 421 [51%] of 823; p=0·92). No interactions were HR=hazard ratio.
noted between treatment and sex (p=0·13), ethnic origin
(p=0·51), age (p=0·49), or deseasonalised 25(OH)D Discussion
(p=0·80). Monthly supplementation of 100 000 IU colecalciferol
In the placebo group, reporting of falls was higher in (vitamin D) taken for 2·5–4·2 years (mean 3·4 years)
3
women than in men (644 [60%] of 1082 vs 682 [48%] was not associated with a significant difference in risk of
of 1435; HR 1·42, 95% CI 1·27–1·59; p<0·0001) and in falls or fractures compared with placebo in this
those who had a fall in the 4 weeks before the study (1·73, community-based randomised controlled trial in
1·39–2·15; p<0·0001). Risk of falls increased with age, individuals predominantly without known osteoporosis.
but was not associated with ethnic origin, physical activity, Although the statistical power of the study to detect a
or baseline 25(OH)D, after adjustment for covariates difference in fracture risk was low, no evidence was
(appendix p 3). The appendix (p 4) shows the number of recorded of any reduced risk of fractures in participants
participants reporting falls stratified by age and sex. assigned vitamin D supplementation.
Non-vertebral fractures were identified in 292 (6%) of The association between vitamin D deficiency and
5108 participants during follow-up (primary fracture rickets and osteomalacia is well established, and the
outcome), with 156 (6%) of 2558 people allocated vitamin D general consensus is that concentrations below 25 nmol/L
supplementation and 136 (5%) of 2550 assigned placebo are associated with greatly increased risk of these
reporting a fracture (after adjustment for age, sex, and conditions.1 However, the optimum vitamin D status for
ethnic origin, HR 1·15, 95% CI 0·92–1·45; after further other health outcomes is subject to debate in terms of the
adjustment for history of recent fall, physical activity, and optimum concentration in blood of 25(OH)D above
baseline 25[OH]D, HR 1·19, 0·94–1·50; table 2). No deficiency levels1,14,20 and the oral vitamin D dose needed to
difference in cumulative risk of fracture was noted between maintain particular blood concentrations of 25(OH)D
participants allocated vitamin D supplementation and those when sunl ight exposure is inadequate.
assigned placebo (figure 3). Addition of 13 spinal fractures Most trials of vitamin D supplementation for
to the 292 non-vertebral fractures, to obtain the total number prevention of falls or fracture have focused on groups at
of fractures (305 of 5108), did not change estimates by much high risk of fracture—eg, women, older people, and
(age, sex, and ethnic origin adjusted HR 1·14, 95% CI institutionalised individuals (ie, those living in a nursing
0·91–1·42). In the placebo group, fractures were more or long-term care home). Moreover, trials have been done
common in women than in men (80 [7%] of 1093 vs 56 [4%] in predominantly white populations. The current
of 1357; HR 1·77, 95% CI 1·24–2·52; p=0·002) but were community-based trial included men, had a wide age
not associated with age, ethnic origin, history of recent range (50–84 years) of participants, and included
falls, physical activity, or baseline 25(OH)D, after different ethnic groups who have been documented to
adjustment for covariates (appendix p 5). Exploratory have a high prevalence of vitamin D deficiency.21
analyses stratifying results by baseline 25(OH)D either less Evidence in a 2014 review did not support the
than 25 nmol/L or greater than or equal to 75 nmol/L hypothesis that supplementation with only vitamin D
showed no heterogeneity (appendix p 6). reduced the risk of falls or fractures,22 in striking contrast
www.thelancet.com/diabetes-endocrinology Published online April 28, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30103-1 7
)%(
erutcarf
a
dah
gnivah
noitroporP
Vitamin D
Placebo
Articles
to findings of previous meta-analyses. For example, with adherence, compared with a daily dose for several years.12
respect to falls, the conclusion of a 2010 meta-analysis— Findings of pharmacokinetic studies indicate a peak at
based on ten studies meeting inclusion criteria—was 7 days after a 100 000 IU dose of vitamin D, with mean
that 200–1000 IU daily vitamin D reduced falls by 14% values declining linearly to baseline concentrations by
compared with calcium or placebo,9 a conclusion 84 days.13
supported by a review in 2012 that suggested a 17% lower In an early trial using 100 000 IU oral colecalciferol
risk of falling with a median oral daily dose of 800 IU every 4 months (equivalent to about 800 IU daily), a 22%
vitamin D.10 However, in trials published since those reduction in fractures was reported in a community-
reviews, an increased falls risk with bolus vitamin D based population of men and women older than 65 years.28
supplementation has been reported,23,24 leading to a more However, later trials using large intermittent bolus doses
cautious re-evaluation highlighting the need for evidence reported no benefits;29 indeed, in one trial of an annual
in various study populations and different dosage autumn dose of 500 000 IU vitamin D in 2256 community-
regimens. Some of the differences in conclu sions from dwelling older women at high risk of fractures, a
overlapping meta-analyses of vitamin D supplements significantly increased risk of falls and fractures was
and falls have been attributed to method ological reported (HR 1·15 and HR 1·26, respectively).24 Sanders
variations in using data from the same trials,25 such as and colleagues24 noted a temporal pattern in increased
inclusion criteria and data extraction. rates of falls in the 3 months immediately after the bolus
In terms of fractures, the 43% reduction in hip fractures and postulated that either very high levels of vitamin D
reported in a trial of 3270 institutionalised women (ie, metabolites or a subsequent decrease in concentration of
those living in a nursing or long-term care home; these metabolites, or both, might be causal. In a 2016
mean age 84 years) who had very low 25(OH)D levels trial, increased falls were reported with monthly 60 000 IU
consistent with osteomalacia and who were given a daily vitamin D compared with monthly 24 000 IU vitamin D,
3 3
800 IU vitamin D and 1200 mg calcium supplement over which accords with this finding, with the falls risk highest
18 months4 has not been observed consistently in in people with the highest vitamin D levels.7 We did not
subsequent trials, whether for primary or secondary have exit vitamin D levels for most participants in ViDA
prevention of fractures.5 A meta-analysis of such trials to enable these analyses. Findings of a review of the
suggested a possible weak inverse association of vitamin D various trials to compare high-dose intermittent supple-
and calcium supplementation with hip fractures in mentation with more frequent dosing suggested that the
high-risk groups, but no overall effect of vitamin D mode of administration of vitamin D resulting in an
supplementation alone on fracture risk.26 These acute increase in concentrations in blood of 25(OH)D
inconsistent findings have been attributed variously to (through large oral doses) might play a part in the
differences in the baseline vitamin D status of the study physiological effects.29
populations and the dose, frequency, and mode of Uncertainty surrounds what the optimum amounts of
administration of vitamin D, as well as the addition or not 25(OH)D might be above the suggested deficiency
of calcium supplementation. Questions persist about concentrations of less than 25–30 nmol/L in relation to
optimum vitamin D status and the dose and frequency of various health outcomes, and these values could differ
administration of vitamin D supplementation. depending on the health outcome; thresholds might vary
In the ViDA trial, we aimed to raise concentrations in for fractures or cardiovascular disease or in different ethnic
serum of 25(OH)D to 80–100 nmol/L, which are groups.1 For bone health, no additional benefit might be
physiological concentrations recorded in young adults in gained above concentrations associated with deficiency,
tropical latitudes and which findings of observational and possible adverse effects could arise at high
studies suggested were optimum for health at the time concentrations (>70 nmol/L), which might be associated
this trial was designed.14 Findings of initial studies with increased bone turnover. In this context, the mean
suggested that fairly high doses of vitamin D were baseline 25(OH)D concentration of this population was
needed to achieve these concentrations of 25(OH)D, and higher (61 nmol/L) than the average concentrations
thus to be effective in fracture prevention. In a study from other trial populations. In the trial by Trivedi and
of fracture reduction, Chapuy and colleagues4 used colleagues28 of 100 000 IU vitamin D every 4 months,
800 IU vitamin D daily; later trials in which no effects of fracture reduction was reported with increased concen-
vitamin D were reported on fractures—eg, the Women’s trations of 25(OH)D in the vitamin D treatment group,
Health Initiative—used smaller doses of 400 IU daily.27 from an average baseline of 53 nmol/L to 74 nmol/L.
In the ViDA study, the monthly bolus of 100 000 IU Although the aim of the ViDA trial was to increase
colecalciferol was equivalent to an intake of roughly concentrations to 80–100 nmol/L, the mean amounts
3000 IU vitamin D a day, which is the approximate recorded in participants allocated vitamin D supple men-
requirement to achieve these concentrations of 25(OH)D tation were substantially higher, around 120 nmol/L on
in blood when sunlight exposure is inadequate. Since average, and more than twice that noted in individuals
25(OH)D has a long half-life in blood, use of a bolus for allocated placebo. Nevertheless, although U-shaped associ-
supplementation had perceived advantages of improving ations between amounts of 25(OH)D and fractures and
8 www.thelancet.com/diabetes-endocrinology Published online April 28, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30103-1
Articles
falls could account for the overall lack of effect on risk limits external validity, although this shortfall is common
of falls and fractures (if supplementation resulted in some for trials for which the priority is to maximise internal
individuals having very high concentrations that might validity. Second, later on in the study, capsules were sent
increase risk), we noted no differences in falls and fractures to participants every 4 months. Although no checks were
associated with supplementation in individuals stratified made as to whether four capsules were taken on one
by baseline 25(OH)D status. Thus, even people with low occasion rather than monthly, participants had previously
amounts seemed to derive no fracture risk reduction from been taking one capsule monthly for at least 2 years,
supplementation. Further stratification of results according reminder letters were sent monthly to take one capsule,
to baseline 25(OH)D less than 25 nmol/L or at least and no cases of hypercalcaemia were detected in the
75 nmol/L showed no heterogeneity and provided no subset returning annually for blood tests. Third, use of
support for the hypothesis that supplementation might be participant self-reports to identify falls could have resulted
effective in individuals with deficiency or that increasing in a random measurement error for this outcome,
25(OH)D in people with high concentrations (≥75 nmol/L) attenuating any effect from vitamin D. However, we used
might be adverse and thereby counterbalance any potential the standard questionnaire wording recommended for
benefit in those with low amounts of 25(OH)D. this outcome15 and obtained falls data every month, as
The ViDA trial was designed to test the effect of recommended,15 for most of the follow-up period.
vitamin D supplementation alone, rather than in Although the questionnaire was not validated in this
conjunction with calcium supplements. Although findings population, and we were not able to verify such a large
of some meta-analyses have suggested that both calcium number of falls by follow-up phone calls, the expected
and vitamin D are necessary for a benefit on fractures,1,5 increased risk of falls seen for female sex, older age, and
results are inconsistent and heterogeneity could be recent history of falls (appendix p 3) support the validity
accounted for not only by the differing doses of vitamin D of our measure for this outcome. Fourth, our study had
but also by the dose and type of calcium supplement. low statistical power for fracture outcome, particularly in
The ViDA trial has several strengths. First, adherence participants with vitamin D deficiency, in age and sex
was excellent. We assessed adherence in a random subset subgroups, or for fracture subsites. Although falls data
of participants and showed a substantial increase in were gathered, the falls outcome was post hoc without a
mean blood 25(OH)D concentrations over 3 years in the prespecified statistical analysis plan. However, the study
group randomly allocated vitamin D supplementation power for the falls outcome was high, even in the
compared with those assigned placebo. Second, 1270 participants with low vitamin D levels. Finally, we did
ascertainment of fractures used two independent not measure dietary vitamin D or calcium intake at
objective methods: hospital discharges tracked using the baseline. However, based on findings of a national
Ministry of Health unique National Health Index nutrition survey showing that New Zealanders of
number; and the ACC system (the national governmental European ancestry in the study age range had a mean
insurance organisation that covers all New Zealand daily calcium intake of 862 mg for men and 771 mg for
residents for any medical and hospital costs from injury). women, values that are similar to those for the European
Although we did not assess the sensitivity and specificity and North American population, it is unlikely that our
of the fracture data, diagnosed fractures not captured by null results are explained by inadequate intake of
these data will have been very few because both hospitals dietary calcium.
and family doctors have a financial incentive to claim Results from the ViDA trial suggest that a monthly
from the ACC for any costs from treating injuries, dose of 100 000 IU colecalciferol in a healthy, middle-
including both inpatient and outpatient fractures. Thus, aged, and older ambulatory population does not reduce
sensitivity is likely to be very high. Additionally, multiple the risk of fractures or falls over 4 years. Although the
health professionals are usually involved in the study had low power for fracture endpoints, these
management of fractures (family doctors, radiologists, findings—taken in conjunction with results from other
and physiotherapists at the very least). This multi- trials—suggest that use of large monthly bolus doses of
disciplinary teamwork acts as a check against fraudulent vitamin D does not confer overall benefit. Further study
ACC claims by health professionals, giving confidence is needed to assess the effects of daily dosing of
that the specificity of the fracture data is also very high. vitamin D, with or without calcium supplementation,
Third, one of the aims of the ViDA trial was to include and international trials are ongoing (eg, VITAL in
population subgroups in which data are sparse; the the USA [NCT01169259]; DO-HEALTH in Europe
Māori and south Asian ethnic groups in New Zealand are [NCT01745263]; and FIND in Finland [NCT01463813]).
at particular risk of vitamin D deficiency.21 Although
Contributors
statistical power was limited in the various subgroups, RS, AWS, CMML, LT, K-TK, and CAC Jr had the idea for the study and
no evidence of heterogeneity of effect was seen in any of contributed to study design, data analysis, and data interpretation. RS,
AWS, DW, and CMML contributed to data acquisition. K-TK and RS
the subgroups examined.
drafted the report and AWS, DW, CMML, LT, and CAC Jr contributed to
Our study has limitations. First, the low proportion of
critical revision for important intellectual content. AWS and RS did the
people invited to participate who were randomly assigned statistical analysis.
www.thelancet.com/diabetes-endocrinology Published online April 28, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30103-1 9
Articles
Declaration of interests 15 Lamb SE, Jorstad-Stein EC, Hauer K, Becker C. Development of a
We declare no competing interests. common outcome data set for fall injury prevention trials: the
Prevention of Falls Network Europe consensus. J Am Geriatr Soc
Acknowledgments 2005; 53: 1618–22.
This study was funded by the Health Research Council of New Zealand 16 Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose
(grant 10/400) and the Accident Compensation Corporation of vitamin D supplementation on cardiovascular disease in the vitamin
New Zealand. D assessment study: a randomized clinical trial. JAMA Cardiol 2017;
published online April 5. DOI:10.1001/jamacardio.2017.0175.
References
1 Ross AC, Taylor CL, Yaktine AL, del Valle H. Dietary reference 17 Kerse N, Flicker L, Pfaff JJ, et al. Falls, depression and antidepressants
intakes for calcium and vitamin D. Washington: The National in later life: a large primary care appraisal. PLoS One 2008; 3: e2423.
Academies Press, 2011. 18 Brown P, McNeill R, Leung W, Radwan E, Willingale J. Current and
2 Cauley JA, Danielson ME, Boudreau R, et al. Serum future economic burden of osteoporosis in New Zealand.
25-hydroxyvitamin D and clinical fracture risk in a multiethnic Appl Health Econ Health Policy 2011; 9: 111–23.
cohort of women: the Women’s Health Initiative (WHI). 19 Sachs MC, Shoben A, Levin GP, et al. Estimating mean annual
J Bone Miner Res 2011; 26: 2378–88. 25-hydroxyvitamin D concentrations from single measurements:
3 Khaw KT, Luben R, Wareham N. Serum 25-hydroxyvitamin D, the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr 2013;
mortality, and incident cardiovascular disease, respiratory disease, 97: 1243–51.
cancers, and fractures: a 13-y prospective population study. 20 Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members
Am J Clin Nutr 2014; 100: 1361–70. respond to Endocrine Society vitamin D guideline.
4 Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D and calcium to J Clin Endocrinol Metab 2012; 97: 1146–52.
prevent hip fractures in elderly women. N Engl J Me3 d 1992; 21 Rockell JE, Skeaff CM, Williams SM, Green TJ. Serum
327: 1637–42. 25-hydroxyvitamin D concentrations of New Zealanders aged
5 Avenell A, Mak JC, O’Connell D. Vitamin D and vitamin D 15 years and older. Osteoporos Int 2006; 17: 1382–89.
analogues for preventing fractures in post-menopausal women 22 Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and
and older men. Cochrane Database Syst Rev 2014; 4: CD000227. multiple health outcomes: umbrella review of systematic reviews
6 Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with and meta-analyses of observational studies and randomised trials.
or without calcium supplementation for prevention of cancer and BMJ 2014; 348: g2035.
fractures: an updated meta-analysis for the US Preventive Services 23 Ginde AA, Blatchford P, Breese K, et al. High-dose monthly
Task Force. Ann Intern Med 2011; 155: 827–38. vitamin D for prevention of acute respiratory infection in older
7 Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly long-term care residents: a randomized clinical trial.
high-dose vitamin D treatment for the prevention of functional decline: J Am Geriatr Soc 2017; 65: 496–503.
a randomized clinical trial. JAMA Intern Med 2016; 176: 175–83. 24 Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral
8 Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for vitamin D and falls and fractures in older women: a randomized
preventing falls in older people living in the community. controlled trial. JAMA 2010; 303: 1815–22.
Cochrane Database Syst Rev 2012; 9: CD007146. 25 Bolland MJ, Grey A, Reid IR. Differences in overlapping
9 Kalyani RR, Stein B, Valiyil R, Manno R, Maynard JW, Crews DC. meta-analyses of vitamin D supplements and falls.
Vitamin D treatment for the prevention of falls in older adults: J Clin Endocrinol Metab 2014; 99: 4265–72.
systematic review and meta-analysis. J Am Geriatr Soc 2010; 26 Avenell A, MacLennan GS, Jenkinson DJ, et al. Long-term follow-up
58: 1299–310. for mortality and cancer in a randomized placebo-controlled trial of
10 Moyer VA. Prevention of falls in community-dwelling older adults: vitamin D(3) and/or calcium (RECORD trial).
US Preventive Services Task Force recommendation statement. J Clin Endocrinol Metab 2012; 97: 614–22.
Ann Intern Med 2012; 157: 197–204. 27 Cauley JA, Chlebowski RT, Wactawski-Wende J, et al. Calcium plus
11 Uusi-Rasi K, Patil R, Karinkanta S, et al. Exercise and vitamin D in vitamin D supplementation and health outcomes five years after
fall prevention among older women: a randomized clinical trial. active intervention ended: the Women’s Health Initiative.
JAMA Intern Med 2015; 175: 703–11. J Womens Health (Larchmt) 2013; 22: 915–29.
12 Scragg R, Waayer D, Stewart AW, et al. The Vitamin D Assessment 28 Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D 3
(ViDA) Study: design of a randomized controlled trial of vitamin D (cholecalciferol) supplementation on fractures and mortality in men
supplementation for the prevention of cardiovascular disease, acute and women living in the community: randomised double blind
respiratory infection, falls and non-vertebral fractures. controlled trial. BMJ 2003; 326: 469.
J Steroid Biochem Mol Biol 2016; 164: 318–25. 29 Zheng YT, Cui QQ, Hong YM, Yao WG. A meta-analysis of high
13 Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose, intermittent vitamin D supplementation among older adults.
dose of cholecalciferol. Am J Clin Nutr 2008; 87: 688–91. PLoS One 2015; 10: e0115850.
14 Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T,
Dawson-Hughes B. Estimation of optimal serum concentrations of
25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr
2006; 84: 18–28.
10 www.thelancet.com/diabetes-endocrinology Published online April 28, 2017 http://dx.doi.org/10.1016/S2213-8587(17)30103-1
